Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Hendifar

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
World Journal of Gastrointestinal Surgery|October 7, 2020
Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapySungjin Kim, Timothy P DiPeri, Michelle Guan, et al.
The American Journal of Gastroenterology|September 3, 2024
Incidence Trends in Upper Gastrointestinal Cancer in Young Adults: A Nationwide Time-Trend Analysis Using 2001-2019 US Cancer Statistics DatabasesJeff Liang, Ryan Rastegar, Mohamad El Helou, et al.
The American Journal of Gastroenterology|August 10, 2023
Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular CarcinomaYee Hui Yeo, Jeff Liang, Marie Lauzon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
Factors Associated With Detection and Survival of T1 Hepatocellular Carcinoma in the United States: National Cancer Database AnalysisJu Dong Yang, Michael Luu, Amit G Singal, et al.
Gastroenterology|March 6, 2019
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersAatur D Singhi, Ben George, Joel R Greenbowe, et al.
Ebiomedicine|January 13, 2019
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancerRichard Tuli, Stephen L Shiao, Nicholas Nissen, et al.
Cancers|February 13, 2026
Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001Elena Gabriela Chiorean, Sheela R Damle, David B Zhen, et al.
JCO Precision Oncology|April 27, 2022
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case SeriesMargherita Ambrosini, Marzia Del Re, Paolo Manca, et al.
Gastroenterology|February 12, 2023
Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001-2018Yazan Abboud, Jamil S Samaan, Janice Oh, et al.
The Lancet. Oncology|November 18, 2021
<sup>177</sup>Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trialJonathan R Strosberg, Martyn E Caplin, Pamela L Kunz, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
World Journal of Gastrointestinal Surgery|October 7, 2020
Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapySungjin Kim, Timothy P DiPeri, Michelle Guan, et al.
The American Journal of Gastroenterology|September 3, 2024
Incidence Trends in Upper Gastrointestinal Cancer in Young Adults: A Nationwide Time-Trend Analysis Using 2001-2019 US Cancer Statistics DatabasesJeff Liang, Ryan Rastegar, Mohamad El Helou, et al.
The American Journal of Gastroenterology|August 10, 2023
Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular CarcinomaYee Hui Yeo, Jeff Liang, Marie Lauzon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
Factors Associated With Detection and Survival of T1 Hepatocellular Carcinoma in the United States: National Cancer Database AnalysisJu Dong Yang, Michael Luu, Amit G Singal, et al.
Gastroenterology|March 6, 2019
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersAatur D Singhi, Ben George, Joel R Greenbowe, et al.
Ebiomedicine|January 13, 2019
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancerRichard Tuli, Stephen L Shiao, Nicholas Nissen, et al.
Cancers|February 13, 2026
Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001Elena Gabriela Chiorean, Sheela R Damle, David B Zhen, et al.
JCO Precision Oncology|April 27, 2022
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case SeriesMargherita Ambrosini, Marzia Del Re, Paolo Manca, et al.
Gastroenterology|February 12, 2023
Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001-2018Yazan Abboud, Jamil S Samaan, Janice Oh, et al.
The Lancet. Oncology|November 18, 2021
<sup>177</sup>Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trialJonathan R Strosberg, Martyn E Caplin, Pamela L Kunz, et al.
Pageof 9